LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $94.00

LeMaitre Vascular (NASDAQ:LMAT) had its price target upped by Wells Fargo & Company from $87.00 to $94.00 in a report released on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the medical instruments supplier’s stock.

Several other equities analysts also recently issued reports on LMAT. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Roth Mkm reiterated a “buy” rating and issued a $108.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Citizens Jmp increased their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Finally, Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Hold” and a consensus price target of $105.80.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $108.18 on Thursday. The business has a 50 day simple moving average of $87.02 and a 200 day simple moving average of $88.36. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. The company has a market capitalization of $2.45 billion, a PE ratio of 43.10, a price-to-earnings-growth ratio of 2.19 and a beta of 0.72. LeMaitre Vascular has a one year low of $71.42 and a one year high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 23.13%.The business’s revenue was up 15.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, sell-side analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Thursday, March 12th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio is 31.87%.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in the company. M&T Bank Corp increased its position in LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock worth $32,283,000 after purchasing an additional 381,061 shares during the period. Goldman Sachs Group Inc. grew its position in shares of LeMaitre Vascular by 144.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after buying an additional 231,157 shares during the period. First Trust Advisors LP raised its stake in shares of LeMaitre Vascular by 35.4% during the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock worth $72,541,000 after buying an additional 216,919 shares during the last quarter. Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in LeMaitre Vascular by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after buying an additional 105,921 shares during the period. Institutional investors own 84.64% of the company’s stock.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and above‑consensus guidance: LeMaitre reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.); management raised Q1 and FY2026 EPS and revenue guidance, signaling continued top‑line momentum. Press Release
• Positive Sentiment: Dividend increase: Company raised the quarterly dividend 25% to $0.25/share (ex‑dividend March 12), returning cash to shareholders and supporting income‑oriented demand.
• Positive Sentiment: Analyst bullishness: Multiple firms raised ratings/targets — Citizens JMP to $118 (market outperform) and Roth MKM reaffirmed Buy and raised target to $117 — these are constructive for sentiment. Analyst Note
• Neutral Sentiment: Investor outreach: Management will participate in five investor conferences in March, increasing visibility and allowing direct Q&A with investors. Conference Notice
• Neutral Sentiment: Earnings call coverage and transcripts are available for deeper color on drivers (procedure volumes, product mix, backlog) for investors doing fundamental diligence. Earnings Transcript
• Negative Sentiment: Mixed analyst targets; some firms still imply downside: Wells Fargo raised its target but keeps an “equal weight” rating with a $94 target (below current price), and a few targets remain lower than the stock’s recent level — this can trigger profit‑taking or short‑term selling. Analyst Notes

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.